Stimuli-Responsive Nanocarriers for Transdermal siRNA Delivery: Mechanisms, Challenges, and Therapeutic Strategies
7 affiliations
- 1School of Life Science and Medicine, Shandong University of Technology, Zibo, 244000, People's Republic of China
- 2School of Medical Informational Engineering, Shandong University of Traditional Chinese Medicine, Jinan, 250355, People's Republic of China
- 3Co-Innovation Center for the Sustainable Forestry in Southern China and Department of Food Science and Technology, Nanjing, 210037, People's Republic of China
- 4College of Light Industry and Food Engineering, Nanjing Forestry University, Nanjing, 210037, People's Republic of China
- 5Department of Clinical Medicine, The First Clinical Medical College, Jinzhou Medical University, Jinzhou, 121001, People's Republic of China
- 6Department of Medical Laboratory Technology, School of Medicine, Hunan Normal University, Changsha, 410006, People's Republic of China
- 7Laboratory of Neurological Diseases and Brain Function, the Affiliated Hospital, Southwest Medical University, Luzhou, 646000, People's Republic of China
Abstract
Background: Small interfering RNA (siRNA) holds therapeutic promise for dermatological diseases, but clinical translation is limited by the stratum corneum barrier and the instability of naked siRNA. Nanocarrier-based systems offer effective solutions by enhancing skin penetration, improving siRNA stability, and enabling targeted intracellular delivery. Methods: This review synthesizes current evidence on nanocarrier-mediated transdermal siRNA delivery. Key design parameters: particle size, surface charge, degradability, and morphology are evaluated for their roles in skin permeation and intracellular trafficking. Stimuli-responsive nanocarriers (pH, enzymatic, light, temperature) and physical enhancement strategies, including microneedles, sonophoresis, and laser ablation, are also reviewed. Results: Lipid-polymer hybrid nanoparticles demonstrate notable advantages in stability, biocompatibility, and co-delivery capability. Stimuli-responsive systems enable spatiotemporal control of siRNA release, while physical enhancement technologies significantly improve cutaneous permeability. Disease-specific delivery strategies tailored to pathological microenvironments including psoriasis, melanoma, and chronic wounds illustrate the feasibility of adapting material composition, structural parameters, and responsiveness to different therapeutic contexts. Conclusion: Advances in intelligent nanomaterials, responsive carrier engineering, and physical facilitation approaches provide a solid foundation for clinically viable transdermal siRNA therapies. Future development will benefit from integrating precise release control with disease-tailored delivery strategies to overcome biological barriers and optimize therapeutic outcomes.
Related
- Next-generation microneedle platforms for transdermal therapeutics: a comprehensive review of innovations and challenges
- Advanced cell-laden hydrogels for diabetic wound healing: Biomaterial design, therapeutic mechanisms, and translational challenges
- Targeting neddylation in cancer: molecular mechanisms, translational advances, and therapeutic challenges
- Advancements in therapeutic targets and drug development for hyperuricemia: Mechanisms, progress, and challenges
- Microarray patches for transdermal drug delivery: a critical narrative review of technological innovations, CMC challenges, clinical translation, and global health implementation
BibTeX
@article{jian2026stimuliresponsive,
title = {{Stimuli-Responsive Nanocarriers for Transdermal siRNA Delivery: Mechanisms, Challenges, and Therapeutic Strategies}},
author = {Yanmin Jian and Minghui Ban and Zhenyang Yan and Yue Wang and Ziyan Che and Wenwen Ren and Yuan Cao and Zao Wang and Yue Yuan},
journal = {International Journal of Nanomedicine},
year = {2026},
month = jun,
doi = {10.2147/ijn.s595572},
url = {https://doi.org/10.2147/ijn.s595572},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Stimuli-Responsive Nanocarriers for Transdermal siRNA Delivery: Mechanisms, Challenges, and Therapeutic Strategies
AU - Yanmin Jian
AU - Minghui Ban
AU - Zhenyang Yan
AU - Yue Wang
AU - Ziyan Che
AU - Wenwen Ren
AU - Yuan Cao
AU - Zao Wang
AU - Yue Yuan
PY - 2026
DA - 2026/06/01
JO - International Journal of Nanomedicine
DO - 10.2147/ijn.s595572
UR - https://doi.org/10.2147/ijn.s595572
AB - Background: Small interfering RNA (siRNA) holds therapeutic promise for dermatological diseases, but clinical translation is limited by the stratum corneum barrier and the instability of naked siRNA. Nanocarrier-based systems offer effective solutions by enhancing skin penetration, improving siRNA stability, and enabling targeted intracellular delivery. Methods: This review synthesizes current evidence on nanocarrier-mediated transdermal siRNA delivery. Key design parameters: particle size, surface charge, degradability, and morphology are evaluated for their roles in skin permeation and intracellular trafficking. Stimuli-responsive nanocarriers (pH, enzymatic, light, temperature) and physical enhancement strategies, including microneedles, sonophoresis, and laser ablation, are also reviewed. Results: Lipid-polymer hybrid nanoparticles demonstrate notable advantages in stability, biocompatibility, and co-delivery capability. Stimuli-responsive systems enable spatiotemporal control of siRNA release, while physical enhancement technologies significantly improve cutaneous permeability. Disease-specific delivery strategies tailored to pathological microenvironments including psoriasis, melanoma, and chronic wounds illustrate the feasibility of adapting material composition, structural parameters, and responsiveness to different therapeutic contexts. Conclusion: Advances in intelligent nanomaterials, responsive carrier engineering, and physical facilitation approaches provide a solid foundation for clinically viable transdermal siRNA therapies. Future development will benefit from integrating precise release control with disease-tailored delivery strategies to overcome biological barriers and optimize therapeutic outcomes.
SN - 1176-9114
SN - 1178-2013
ER -